Download PDF
CC BY 4.0 · Libyan International Medical University Journal
DOI: 10.1055/s-0045-1809043
Review Article

Pharmacological Profile and Mechanisms of Cardiovascular Protective Effects of Statins: An Update

Abdalla Salem Elhwuegi 
1   Libyan International Medical University, Benghazi, Libya
,
Mustafa M. Elfakhri
2   Faculty of Medicine, Benghazi, Libya
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints


Abstract

This review article highlights recent developments in the clinical pharmacology of statins. A thorough literature search was performed using PubMed Central, Scopus, and Google Scholar, focusing on keywords related to statin kinetics, mechanisms, cardiovascular protection, side effects, and variations in individual responses. Understanding the pharmacokinetics of statins is essential for maximizing their therapeutic effects while reducing side effects and potential drug interactions. Statins have varying degrees of lipophilicity, resulting in different kinetic profiles that affect their bioavailability, elimination, and interactions with other drugs.

The main mechanism by which statins lower cholesterol in blood is by inhibiting liver 3-hydroxy-3-methylglutaryl-CoA reductase, thereby increasing low-density lipoprotein receptor expression on hepatocytes and decreasing its plasma levels. This will ultimately reduce the risk of cardiovascular events. Statins also have antithrombotic and anti-inflammatory effects by increasing the availability of nitric oxide, inhibiting procoagulant proteins, and inhibiting platelet activation, all of which contribute to cardiovascular protection. Several clinical evidences support the effectiveness of statins in preventing venous thromboembolism and acute coronary syndrome. However, statins are associated with an increased risk of new-onset diabetes, particularly with high-intensity statins, necessitating careful monitoring in high-risk patients. Additionally, there is variability in patient responses to statin therapy, influenced by genetic polymorphisms and biological differences, highlighting the need for personalized treatment strategies. As clinical guidelines continue to evolve, incorporating genetic and biological factors will be vital for optimizing statin therapy and managing cardiovascular risks. In conclusion, there is substantial evidence that statins still play a vital role in preventing cardiovascular disease, necessitating a comprehensive approach that combines pharmacological interventions with lifestyle modifications to enhance patient outcomes.

Keywords

cardiovascular protective effects - personalized treatment of statins - statin kinetics - statin side effects - statins


Publication History

Received: 01 January 2025

Accepted: 06 April 2025

Article published online:
19 May 2025

© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Tolman KG. The liver and lovastatin. Am J Cardiol 2002; 89 (12) 1374-1380
    PubMedSearch in Google Scholar
  • 2 Tobe SW, Stone JA, Anderson T. et al. Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update. CMAJ 2018; 190 (40) E1192-E1206
    PubMedSearch in Google Scholar
  • 3 Dennison Himmelfarb CR, Beckie TM, Allen LA. et al; American Heart Association Council on Cardiovascular and Stroke Nursing, American Heart Association Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Quality of Care and Outcomes Research; Council on Hypertension; Council on the Kidney in Cardiovascular Disease; Council on Lifelong Congenital Heart Disease and Heart Health in the Young; Council on Lifestyle and Cardiometabolic Health; Council on Peripheral Vascular Disease; Council on Epidemiology and Prevention; and Stroke Council. Shared decision-making and cardiovascular health: a scientific statement from the American Heart Association. Circulation 2023; 148 (11) 912-931
    CrossrefPubMedSearch in Google Scholar
  • 4 Cid-Conde L, López-Castro J. Pharmacokinetic Aspects of Statins [Internet]. Cardiovascular Risk Factors in Pathology. IntechOpen; 2021. . Accessed April 17, 2025 at: http://dx.doi.org/10.5772/intechopen.91910
    CrossrefSearch in Google Scholar
  • 5 Cid-Conde L, López-Castro J. Pharmacokinetic Aspects of Statins. 2020 . Accessed April 17, 2025 at: http://dx.doi.org/10.5772/INTECHOPEN.91910
    CrossrefSearch in Google Scholar
  • 6 Hu M, Tomlinson B. Evaluation of the pharmacokinetics and drug interactions of the two recently developed statins, rosuvastatin and pitavastatin. Expert Opin Drug Metab Toxicol 2014; 10 (01) 51-65
    PubMedSearch in Google Scholar
  • 7 Kanukula R, Salam A, Rodgers A, Kamel B. Pharmacokinetics of rosuvastatin: a systematic review of randomised controlled trials in healthy adults. Clin Pharmacokinet 2021; 60 (02) 165-175
    PubMedSearch in Google Scholar
  • 8 DeBose-Boyd RA. Feedback regulation of cholesterol synthesis: sterol-accelerated ubiquitination and degradation of HMG CoA reductase. Cell Res 2008; 18 (06) 609-621
    CrossrefPubMedSearch in Google Scholar
  • 9 Schade DS, Duro T, Eaton RP. Optimal prescribing of statins to reduce cardiovascular disease. Am J Med 2023; 136 (12) 1133-1135
    PubMedSearch in Google Scholar
  • 10 von Eckardstein A, Nordestgaard BG, Remaley AT, Catapano AL. High-density lipoprotein revisited: biological functions and clinical relevance. Eur Heart J 2023; 44 (16) 1394-1407
    PubMedSearch in Google Scholar
  • 11 Byrne P, Demasi M, Jones M, Smith SM, O'Brien KK, DuBroff R. Evaluating the association between low-density lipoprotein cholesterol reduction and relative and absolute effects of statin treatment: a systematic review and meta-analysis. JAMA Intern Med 2022; 182 (05) 474-481
    PubMedSearch in Google Scholar
  • 12 Galanti K, Di Marino M, Mansour D. et al. Current antithrombotic treatments for cardiovascular diseases: a comprehensive review. Rev Cardiovasc Med 2024; 25 (08) 281
    PubMedSearch in Google Scholar
  • 13 Chen WH, Chen CH, Hsu MC, Chang RW, Wang CH, Lee TS. Advances in the molecular mechanisms of statins in regulating endothelial nitric oxide bioavailability: Interlocking biology between eNOS activity and L-arginine metabolism. Biomed Pharmacother 2024; 171: 116192
    PubMedSearch in Google Scholar
  • 14 Siniscalchi C, Basaglia M, Riva M. et al. Statins effects on blood clotting: a review. Cells 2023; 12 (23) 2719
    PubMedSearch in Google Scholar
  • 15 Blanco-Colio LM, Tuñón J, Martín-Ventura JL, Egido J. Anti-inflammatory and immunomodulatory effects of statins. Kidney Int 2003; 63 (01) 12-23
    PubMedSearch in Google Scholar
  • 16 Owens III AP, Mackman N. The antithrombotic effects of statins. Annu Rev Med 2014; 65 (01) 433-445
    PubMedSearch in Google Scholar
  • 17 Sexton T, Wallace EL, Smyth SS. Anti-thrombotic effects of statins in acute coronary syndromes: at the intersection of thrombosis, inflammation, and platelet-leukocyte interactions. Curr Cardiol Rev 2016; 12 (04) 324-329
    CrossrefPubMedSearch in Google Scholar
  • 18 Henein MY, Vancheri S, Longo G, Vancheri F. The role of inflammation in cardiovascular disease. Int J Mol Sci 2022; 23 (21) 12906
    PubMedSearch in Google Scholar
  • 19 Gonzalez AL, Dungan MM, Smart CD, Madhur MS, Doran AC. Inflammation resolution in the cardiovascular system: arterial hypertension, atherosclerosis, and ischemic heart disease. Antioxid Redox Signal 2024; 40 (4-6): 292-316
    PubMedSearch in Google Scholar
  • 20 Yazdanpanah M, Yazdanpanah N, Chardoli M, Dehghan A. Role of interleukin 6 signaling pathway in the anti-inflammatory effects of statins on coronary artery disease: evidence from Mendelian randomization analysis. Int J Cardiol 2024; 406: 131964
    PubMedSearch in Google Scholar
  • 21 Salloum Z, Dauner K, Li YF. et al. Statin-mediated reduction in mitochondrial cholesterol primes an anti-inflammatory response in macrophages by upregulating Jmjd3. eLife 2024; 13: e85964
    PubMedSearch in Google Scholar
  • 22 German CA, Liao JK. Understanding the molecular mechanisms of statin pleiotropic effects. Arch Toxicol 2023; 97 (06) 1529-1545
    PubMedSearch in Google Scholar
  • 23 Cimmino G, Muscoli S, De Rosa S. et al; Pathogenesis of Atherosclerosis Working Group of the Italian Society of Cardiology. Evolving concepts in the pathophysiology of atherosclerosis: from endothelial dysfunction to thrombus formation through multiple shades of inflammation. J Cardiovasc Med (Hagerstown) 2023; 24 (Suppl. 02) e156-e167
    PubMedSearch in Google Scholar
  • 24 Glynn RJ, Danielson E, Fonseca FA. et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009; 360 (18) 1851-1861
    CrossrefPubMedSearch in Google Scholar
  • 25 Joseph P, Glynn R, Lonn E. et al. Rosuvastatin for the prevention of venous thromboembolism: a pooled analysis of the HOPE-3 and JUPITER randomized controlled trials. Cardiovasc Res 2022; 118 (03) 897-903
    CrossrefPubMedSearch in Google Scholar
  • 26 Farmakis IT, Christodoulou KC, Hobohm L, Konstantinides SV, Valerio L. Lipid lowering for prevention of venous thromboembolism: a network meta-analysis. Eur Heart J 2024; 45 (35) 3219-3227
    CrossrefPubMedSearch in Google Scholar
  • 27 Wu XD, Ye XY, Liu XY. et al. Benefits of intensive lipid-lowering therapies in patients with acute coronary syndrome: a systematic review and meta-analysis. Ann Med 2024; 56 (01) 2389470
    PubMedSearch in Google Scholar
  • 28 Borovac JA, Leth-Olsen M, Kumric M. et al. Efficacy of high-dose atorvastatin or rosuvastatin loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials with GRADE qualification of available evidence. Eur J Clin Pharmacol 2022; 78 (01) 111-126
    PubMedSearch in Google Scholar
  • 29 Xu C, Chen K, Gao Z. et al. Common mechanisms underlying diabetic vascular complications: focus on the interaction of metabolic disorders, immuno-inflammation, and endothelial dysfunction. Cell Commun Signal 2023; 21 (01) 3
    CrossrefPubMedSearch in Google Scholar
  • 30 Spinetti G, Mutoli M, Greco S. et al. Cardiovascular complications of diabetes: role of non-coding RNAs in the crosstalk between immune and cardiovascular systems. Cardiovasc Diabetol 2023; 22 (01) 122
    PubMedSearch in Google Scholar
  • 31 Batten L, Sathyapalan T, Palmer TM. Molecular mechanisms linking diabetes with increased risk of thrombosis. Int J Mol Sci 2023; 24 (24) 17465
    CrossrefPubMedSearch in Google Scholar
  • 32 Usman NUB, Winson T, Basu Roy P. et al. The impact of statin therapy on cardiovascular outcomes in patients with diabetes: a systematic review. Cureus 2023; 15 (10) e47294
    PubMedSearch in Google Scholar
  • 33 Muluk P, Zhu J, Thoma F. et al. Impact of guideline-directed statin intervention for primary prevention in patients with diabetes. Diabetes Care 2023; 46 (12) 2273-2277
    PubMedSearch in Google Scholar
  • 34 Burton CA, Dreschler J, Hernandez L, Maxwell A, Yeager P. Do statins increase the risk for the development of diabetes?. Evid Based Pract 2023; 27 (02) 31-32
    Search in Google Scholar
  • 35 Reith C, Preiss D, Blackwell L. et al; Cholesterol Treatment Trialists' (CTT) Collaboration. Electronic address: ctt@ndph.ox.ac.uk, Cholesterol Treatment Trialists' (CTT) Collaboration. Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis. Lancet Diabetes Endocrinol 2024; 12 (05) 306-319
    PubMedSearch in Google Scholar
  • 36 Parker BA, Capizzi JA, Grimaldi AS. et al. Effect of statins on skeletal muscle function. Circulation 2013; 127 (01) 96-103
    CrossrefPubMedSearch in Google Scholar
  • 37 Gupta A, Thompson D, Whitehouse A. et al; ASCOT Investigators. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet 2017; 389 (10088): 2473-2481
    CrossrefPubMedSearch in Google Scholar
  • 38 Hsia J, MacFadyen JG, Monyak J, Ridker PM. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). J Am Coll Cardiol 2011; 57 (16) 1666-1675
    PubMedSearch in Google Scholar
  • 39 Casula M, Gazzotti M, Bonaiti F. et al; PROSISA Study Group. Reported muscle symptoms during statin treatment amongst Italian dyslipidaemic patients in the real-life setting: the PROSISA Study. J Intern Med 2021; 290 (01) 116-128
    PubMedSearch in Google Scholar
  • 40 Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients – the PRIMO study. Cardiovasc Drugs Ther 2005; 19 (06) 403-414
    PubMedSearch in Google Scholar
  • 41 Colloca L. The nocebo effect. Annu Rev Pharmacol Toxicol 2024; 64 (01) 171-190
    PubMedSearch in Google Scholar
  • 42 Finegold JA, Manisty CH, Goldacre B, Barron AJ, Francis DP. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice. Eur J Prev Cardiol 2014; 21 (04) 464-474
    CrossrefPubMedSearch in Google Scholar
  • 43 Howard JP, Wood FA, Finegold JA. et al. Side effect patterns in a crossover trial of statin, placebo, and no treatment. J Am Coll Cardiol 2021; 78 (12) 1210-1222
    PubMedSearch in Google Scholar
  • 44 Herrett E, Williamson E, Brack K. et al; StatinWISE Trial Group. Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials. BMJ 2021; 372 (135) n135
    CrossrefPubMedSearch in Google Scholar
  • 45 Mansi IA, Sumithran P, Kinaan M. Risk of diabetes with statins. BMJ 2023; 381: e071727
    PubMedSearch in Google Scholar
  • 46 Chen FJ, Yin MC, Chen PY. et al. Association between statin use and diabetes risk in patients with transient ischemic attack. Int J Environ Res Public Health 2022; 19 (21) 13770
    PubMedSearch in Google Scholar
  • 47 Burton JA, Dreschler L, Hernandez A, Maxwell P, Yeager P. Do statins increase the risk for the development of diabetes?. Evid Based Pract 2023; 26 (02) e19-e20
    Search in Google Scholar
  • 48 Björnsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J Hepatol 2012; 56 (02) 374-380
    CrossrefPubMedSearch in Google Scholar
  • 49 Kalantari S, Naghipour M. Statin therapy and hepatotoxicity: appraisal of the safety profile of atorvastatin in hyperlipidemic patients. Adv Biomed Res 2014; 3: 168
    PubMedSearch in Google Scholar
  • 50 Velickova N, Nateva M, Stojanovska S. Liver Enzymes as Biomarkers for Hepatotoxicity of Statins in Patients with Dyslipidemia. In: CMBEBIH 2019: Proceedings of the International Conference on Medical and Biological Engineering, 16–18 May 2019, Banja Luka, Bosnia and Herzegovina. Springer International Publishing; 2020: 611-615
    Search in Google Scholar
  • 51 Ashraf J, Ali Khan M, Minhaj S. et al. Statins and abnormal liver function tests: Is there a correlation?. Cureus 2020; 12 (08) e10145
    PubMedSearch in Google Scholar
  • 52 Samuels KA, Villatoro ALV, Afzal S. et al. Statin therapy and its impact on cognitive functions in elderly patients: a current systematic review. J Adv Med Med Res 2023; 35 (21) 172-185
    Search in Google Scholar
  • 53 Petek B, Häbel H, Xu H. et al. Statins and cognitive decline in patients with Alzheimer's and mixed dementia: a longitudinal registry-based cohort study. Alzheimers Res Ther 2023; 15 (01) 220
    PubMedSearch in Google Scholar
  • 54 Murphy C, Dyer AH, Lawlor B, Kennelly SP. NILVAD Study Group. What is the impact of ongoing statin use on cognitive decline and dementia progression in older adults with mild-moderate Alzheimer disease?. PLoS One 2023; 18 (05) e0285529
    PubMedSearch in Google Scholar
  • 55 Akhabue E, Rittner SS, Carroll JE. et al. Implications of American College of Cardiology/American Heart Association (ACC/AHA) cholesterol guidelines on statin underutilization for prevention of cardiovascular disease in diabetes mellitus among several US networks of community health centers. J Am Heart Assoc 2017; 6 (07) e005627
    PubMedSearch in Google Scholar
  • 56 Sainz de Medrano JI, Brunet Serra M. Influence of pharmacogenetics on the diversity of response to statins associated with adverse drug reactions. Adv Lab Med 2023; 4 (04) 341-352
    PubMedSearch in Google Scholar
  • 57 Romaine SPR, Bailey KM, Hall AS, Balmforth AJ. The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. Pharmacogenomics J 2010; 10 (01) 1-11
    PubMedSearch in Google Scholar
  • 58 Hu M, To KK, Mak VW, Tomlinson B. The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins. Expert Opin Drug Metab Toxicol 2011; 7 (01) 49-62
    PubMedSearch in Google Scholar
  • 59 Cooper-DeHoff RM, Niemi M, Ramsey LB. et al. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and statin-associated musculoskeletal symptoms. Clin Pharmacol Ther 2022; 111 (05) 1007-1021
    PubMedSearch in Google Scholar
  • 60 Zheng E, Madura P, Grandos J. et al. When the same treatment has different response: the role of pharmacogenomics in statin therapy. Biomed Pharmacother 2024; 170: 115966
    PubMedSearch in Google Scholar
  • 61 Hlushchenko I, Islam MM, Tamlander M, Ripatti S, Pfisterer SG. Linking biological variation to outcomes of statin treatment in the general population. medRxiv 2023; (epub ahead of print)
    Crossref
  • 62 Patnaik S, Pollevick ME, Lara-Breitinger KM, Stone NJ. Inter-individual variability in lipid response: a narrative review. Am J Med 2022; 135 (12) 1427-1433.e7
    PubMedSearch in Google Scholar
  • 63 Lu N, Cheng W, Liu D. et al. NLRP3-mediated inflammation in atherosclerosis and associated therapeutics. Front Cell Dev Biol 2022; 10: 823387
    PubMedSearch in Google Scholar
  • 64 Schellnegger M, Hofmann E, Carnieletto M, Kamolz LP. Unlocking longevity: the role of telomeres and its targeting interventions. Front Aging 2024; 5: 1339317
    PubMedSearch in Google Scholar
  • 65 She J, Sun L, Yu Y. et al. A gut feeling of statin. Gut Microbes 2024; 16 (01) 2415487
    PubMedSearch in Google Scholar
  • 66 Rezakhani L, Salimi Z, Zarei F. et al. Protective effects of statins against Alzheimer disease. Ewha Med J 2023; 46 (04) e17
    Search in Google Scholar
  • 67 Guerra B, Recio C, Aranda-Tavío H, Guerra-Rodríguez M, García-Castellano JM, Fernández-Pérez L. The mevalonate pathway, a metabolic target in cancer therapy. Front Oncol 2021; 11: 626971
    PubMedSearch in Google Scholar